Objective Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown
rapid antidepressant effects, but small study groups and inadequate control conditions in …

… Mathew has received research funding or salary support over the last 2 … Mathew has been
named as an inventor on a use patent of ketamine for the treatment of depression. Dr. Mathew …

… Mathew has received lecture or consulting fees from … Charney and Mathew have been named
as an inventor on a use-patent … Mathew has relinquished his claim to any royalties and will …

BACKGROUND: A single subanesthetic (intravenous) IV dose of ketamine might have rapid
but transient antidepressant effects in patients with treatment-resistant depression (TRD). …

Objective: Suicide is a public health crisis with limited treatment options. The authors conducted
a systematic review and individual participant data meta-analysis examining the effects …

Background Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are
both currently used for treatment-resistant major depression, but the comparative …

Scientists have not identified a gene or a series of genes that cause depression. Rather, certain
variations in genes, called polymorphisms, may increase risk for depression. Genes can …

Importance Several studies now provide evidence of ketamine hydrochloride’s ability to produce
rapid and robust antidepressant effects in patients with mood and anxiety disorders that …

Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine was …

Background Preliminary evidence suggests intravenous ketamine has rapid effects on
suicidal cognition, making it an attractive candidate for depressed patients at imminent risk of …